We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Lidds AB (LIDDS) NPV

Sell:0.14 SEK Buy:0.15 SEK Change: No change
Market closed |  Prices as at close on 23 December 2024 | Switch to live prices |
Sell:0.14 SEK
Buy:0.15 SEK
Change: No change
Market closed |  Prices as at close on 23 December 2024 | Switch to live prices |
Sell:0.14 SEK
Buy:0.15 SEK
Change: No change
Market closed |  Prices as at close on 23 December 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Lidds AB (LIDDS) is a Sweden-based company engaged in the development of pharmaceutical products. LIDDS (Local Intelligent Drug Delivery System) uses its drug delivery technology, a parenteral, microparticulate drug carrier matrix, which is administered as a paste that spreads in the tissue and ultimately cures shortly after injection, allowing local treatment at site of disease. It targets primarily solid tumors. The Company’s portfolio includes Liproca Depot, aimed at prostate cancer with possible applications in benign prostate hypertrophy (BPH). The Liproca Depot is a bioresorbable, biocompatible and locally injectable modified release formulation of 2-hydroxyflutamid, prepared as a paste prior to injection.

Contact details

Address:
Virdings Alle 32 B
UPPSALA
754 50
Sweden
Telephone:
+46 (42) 387427
Website:
https://liddspharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
LIDDS
ISIN:
SE0001958612
Market cap:
14.26 million SEK
Shares in issue:
136.46 million
Sector:
Biotechnology
Exchange:
Stockholm Stock Exchange
Country:
Sweden
Currency:
Swedish Krona
Indices:
n/a

Key personnel

  • Jan Toernell
    Chairman of the Board
  • Mats Wiking
    Chief Executive Officer, Chief Financial Officer
  • Niklas Axen
    Head of Formulation and Process Development
  • Roger Belusa
    Chief Medical Officer
  • Kia Bengtsson
    Head of Clinical Development
  • Stefan Gruden
    Head of Pharmaceutical Research & Development and Quality Assurance
  • Anna Torner
    Head of Regulatory Strategy and Regulatory Affairs

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.